Vivek Subbiah recently shared a post by AACR on X, adding:

“Who is ready for AACR24? Such a delight to Chair an amazing futuristic Plenary session on AI at the interface.”

Quoting AACR’s post:

“Some of the most important and compelling topics in cancer research will be explored during plenary sessions each day at AACR24. Learn more in AACR Annual Meeting News.”

Sources: Vivek Subbiah/X and AACR/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor-agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.